ACRX - AcelRx Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
2,196
2,151
7,995
17,357
19,263
Cost of Revenue
5,153
3,976
10,659
12,315
1,770
Gross Profit
-2,957
-1,825
-2,664
5,042
17,493
Operating Expenses
Research Development
8,886
13,137
19,409
21,402
22,488
Selling General and Administrative
34,141
20,765
16,609
15,597
14,203
Total Operating Expenses
43,027
33,902
36,018
36,999
36,691
Operating Income or Loss
-45,984
-35,727
-38,682
-31,957
-19,198
Interest Expense
7,005
12,558
14,037
12,152
5,405
Total Other Income/Expenses Net
-
-
-
0
-756
Income Before Tax
-51,099
-47,147
-52,209
-43,191
-23,639
Income Tax Expense
3
2
-701
-34
760
Income from Continuing Operations
-51,102
-47,149
-51,508
-43,157
-24,399
Net Income
-51,102
-47,149
-51,508
-43,157
-24,399
Net Income available to common shareholders
-51,102
-47,149
-51,508
-43,157
-24,399
Reported EPS
Basic
-
-0.81
-1.10
-0.95
-0.55
Diluted
-
-0.81
-1.10
-0.95
-0.60
Weighted average shares outstanding
Basic
-
58,409
46,884
45,313
44,300
Diluted
-
58,409
46,884
45,313
44,468
EBITDA
-
-34,589
-36,428
-28,987
-16,250